Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid- β vaccine

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Carrera, Iván ^a   Etcheverría, Ignacio ^a   Li, Yi ^b   Fernández Novoa, Lucía ^a   Lombardi, Valter ^a   Vigo, Carmen ^c   Palacios, Hector H ^d   Benberin, Valery V ^e   Cacabelos, Ramón ^f   Aliev, Gjumrakch ^g,h  

^a EuroEspes Biotechnology ^*  (Spain)

^b TEXAS A AND M UNIVERSITY KINGSVILLE   (United States)

^c Neuroscience Division Atlas Pharmaceuticals   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e Academy of Public Administration under the President of the Republic of Kazakhstan   (Kazakhstan)

^f Centro de Investigacion Biomedica EuroEspes   (Spain)

^g GALLY International Biomedical Research Consulting LLC   (United States)

^h University of Atlanta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHOLESTEROL; EB 101; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PRESENILIN 1; SPHINGOSINE 1 PHOSPHATE; UNCLASSIFIED DRUG; VACCINE; AMYLOID BETA PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; EMULSION; HIPPOCAMPUS; IMMUNE SYSTEM; IMMUNOCYTOCHEMISTRY; INFLAMMATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PHYSIOLOGICAL PROCESS; T LYMPHOCYTE; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY, ACTIVE; MICE; MICE, TRANSGENIC; PRESENILIN-1;

EID: 84884849615     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/709145     Document Type: Article

References (69)

1. Tanzi R. E., Bertram L., Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005 120 4 545 555 2-s2.0-13944276825 10.1016/j.cell.2005.02.008 (Pubitemid 40269768)
2. Blennow K., de Leon M. J., Zetterberg H., Alzheimer's disease. The Lancet 2006 368 9533 387 403 2-s2.0-33746310315 10.1016/S0140-6736(06)69113-7 (Pubitemid 44108123)
3. Selkoe D. J., Toward a remembrance of things past: deciphering Alzheimer disease. Harvey Lectures 2003 99 23 45 2-s2.0-23044489284
4. Bertram L., McQueen M., Mullin K., Blacker D., Tanzi R., The AlzGene database. Alzheimer Research Forum, 2012, http://www.alzgene.org
5. Cacabelos R., Martínez R., Fernández-Novoa L., Carril J. C., Lombardi V., Carrera I., Corzo L., Tellado I., Leszek J., McKay A., Takeda M., Genomics of dementia: APOE- and CYP2D6-related pharmacogenetics. International Journal of Alzheimer's Disease 2012 2012 37 2-s2.0-84859762000 10.1155/2012/518901 518901
6. Cacabelos R., Martínez-Bouza R., Genomics and pharmacogenomics of dementia. CNS Neuroscience and Therapeutics 2011 17 5 566 576 2-s2.0-80053189259 10.1111/j.1755-5949.2010.00189.x
7. Cacabelos R., Fernandez-Novoa L., Lombardi V., Kubota Y., Takeda M., Molecular genetics of Alzheimer's disease and aging. Methods and Findings in Experimental and Clinical Pharmacology 2005 27 1 573 2-s2.0-27744509435
8. Walsh D. M., Selkoe D. J., Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004 44 1 181 193 2-s2.0-5344277556 10.1016/j.neuron.2004.09.010 (Pubitemid 39348839)
9. Maier M., Seabrook T. J., Lazo N. D., Jiang L., Das P., Janus C., Lemere C. A., Short amyloid- β (A β) immunogens reduce cerebral A β load and learning deficits in an Alzheimer's disease mouse model in the absence of an A β -specific cellular immune response. Journal of Neuroscience 2006 26 18 4717 4728 2-s2.0-33646938005 10.1523/JNEUROSCI.0381-06.2006 (Pubitemid 44315311)
10. Dodart J., Bales K. R., Gannon K. S., Greene S. J., DeMattos R. B., Mathis C., DeLong C. A., Wu S., Wu X., Holtzman D. M., Paul S. M., Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model. Nature Neuroscience 2002 5 5 452 457 2-s2.0-0036240395 10.1038/nn842 (Pubitemid 34454251)
11. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagoplan S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein. Nature 1995 373 6514 523 527 2-s2.0-0028985574
12. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G., Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. Science 1996 274 5284 99 102 2-s2.0-0029742199 10.1126/science.274.5284.99 (Pubitemid 26332733)
13. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K., Mistl C., Rothacher S., Ledermann B., Bürki K., Frey P., Paganetti P. A., Waridel C., Calhoun M. E., Jucker M., Probst A., Staufenbiel M., Sommer B., Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proceedings of the National Academy of Sciences of the United States of America 1997 94 24 13287 13292 2-s2.0-0011444914 10.1073/pnas.94.24.13287 (Pubitemid 27518514)
14. McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon S., Wang R., Mann D., Dickson D., Duff K., Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiology of Disease 1999 6 4 231 244 2-s2.0-0032886415 10.1006/nbdi.1999.0243 (Pubitemid 29470035)
15. Holcomb L., Gordon M. N., Mcgowan E., Yu X., Benkovic S., Jantzen P., Wright K., Saad I., Mueller R., Morgan D., Sanders S., Zehr C., O'Campo K., Hardy J., Prada C., Eckman C., Younkin S., Hsiao K., Duff K., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine 1998 4 1 97 100 2-s2.0-0031914718 10.1038/nm0198-097 (Pubitemid 28133087)
16. Chishti M. A., Yang D., Janus C., Phinney A. L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P. E., Carlson G. A., St. George-Hyslop P., Westawaya D., Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. The Journal of Biological Chemistry 2001 276 24 21562 21570 2-s2.0-0035877756 10.1074/jbc.M100710200 (Pubitemid 37413154)
17. Gordon M. N., Holcomb L. A., Jantzen P. T., DiCarlo G., Wilcock D., Boyett K. W., Connor K., Melachrino J., O'Callaghan J. P., Morgan D., Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental Neurology 2002 173 2 183 195 2-s2.0-0036175608 10.1006/exnr.2001.7754 (Pubitemid 34151370)
18. Trinchese F., Liu S., Battaglia F., Walter S., Mathews P. M., Arancio O., Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Annals of Neurology 2004 55 6 801 814 2-s2.0-2542584749 10.1002/ana.20101 (Pubitemid 38702575)
19. Jankowsky J. L., Fadale D. J., Anderson J., Xu G. M., Gonzales V., Jenkins N. A., Copeland N. G., Lee M. K., Younkin L. H., Wagner S. L., Younkin S. G., Borchelt D. R., Mutant presenilins specifically elevate the levels of the 42 residue β -amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase. Human Molecular Genetics 2004 13 2 159 170 2-s2.0-1642555780 10.1093/hmg/ddh019 (Pubitemid 38111354)
20. Lu P., Mamiya T., Lu L. L., Mouri A., Zou L. B., Nagai T., Hiramatsu M., Ikejima T., Nabeshima T., Silibinin prevents amyloid β peptide-induced memory impairment and oxidative stress in mice. The British Journal of Pharmacology 2009 157 7 1270 1277 2-s2.0-70349337734 10.1111/j.1476-5381.2009. 00295.x
21. Refolo L. M., Pappolla M. A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K., Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiology of Disease 2000 7 4 321 331 2-s2.0-0034525204 10.1006/nbdi.2000. 0304
22. Patel N. V., Gordon M. N., Connor K. E., Good R. A., Engelman R. W., Mason J., Morgan D. G., Morgan T. E., Finch C. E., Caloric restriction attenuates A β -deposition in Alzheimer transgenic models. Neurobiology of Aging 2005 26 7 995 1000 2-s2.0-14644421534 10.1016/j.neurobiolaging.2004.09.014 (Pubitemid 40312661)
23. Adlard P. A., Perreau V. M., Pop V., Cotman C. W., Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. Journal of Neuroscience 2005 25 17 4217 4221 2-s2.0-18244384051 10.1523/JNEUROSCI.0496-05. 2005 (Pubitemid 40628765)
24. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guldo T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P., Immunization with amyloid- β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999 400 6740 173 177 2-s2.0-0033536163 10.1038/22124 (Pubitemid 29327547)
25. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., Guido T., Hoenow K., Hu K., Johnson-Wood K., Khan K., Kholodenko D., Lee C., Lee M., Motter R., Nguyen M., Reed A., Schenk D., Tang P., Vasquez N., Seubert P., Yednock T., Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America 2003 100 4 2023 2028 2-s2.0-0037452779 10.1073/pnas.0436286100 (Pubitemid 36254567)
26. Carty N. C., Wilcock D. M., Rosenthal A., Grimm J., Pons J., Ronan V., Gottschall P. E., Gordon M. N., Morgan D., Intracranial administration of deglycosylated C-terminal-specific anti-A β antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation 2006 3 article 11 2-s2.0-33745111586 10.1186/1742-2094-3-11 (Pubitemid 43885294)
27. Morgan D., Immunotherapy for Alzheimer's disease. Journal of Alzheimer's Disease 2006 9 425 432 (Pubitemid 44255489)
28. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., Mina E., Kiyatkin A., Glabe C. G., Cribbs D. H., Agadjanyan M. G., Anti-A β 1-11 antibody binds to different β -amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. The Journal of Biological Chemistry 2007 282 31 22376 22386 2-s2.0-34547955761 10.1074/jbc.M700088200 (Pubitemid 47267321)
29. Kotilinek L. A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B. T., Younkin S., Ashe K. H., Reversible memory loss in a mouse transgenic model of Alzheimer's disease. Journal of Neuroscience 2002 22 15 6331 6335 2-s2.0-0036703483 (Pubitemid 35386387)
30. Morgan D., Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochemistry International 2006 49 2 190 194 2-s2.0-33744982670 10.1016/j.neuint.2006.03.017 (Pubitemid 43867077)
31. Orgogozo J., Gilman S., Dartigues J., Laurent B., Puel M., Kirby L. C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B. F., Boada M., Frank A., Hock C., Subacute meningoencephalitis in a subset of patients with AD after A β 42 immunization. Neurology 2003 61 1 46 54 2-s2.0-10744230547 (Pubitemid 36818745)
32. Nicolll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. O., Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: a case report. Nature Medicine 2003 9 4 448 452 2-s2.0-0037393454 10.1038/nm840 (Pubitemid 36460079)
33. Ferrer I., Boada M., Sánchez-Guerra M., Rey M., Costa-Jussá F., Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathology 2004 14 11 20 (Pubitemid 38200585)
34. Gilman S., Koller M., Black R. S., Jenkins L., Griffith S. G., Fox N. C., Eisner L., Kirby L., Rovira M. B., Forette F., Orgogozo J. M., Clinical effects of A β immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005 64 9 1553 1562 2-s2.0-20944448555 10.1212/01.WNL.0000159740. 16984.3C (Pubitemid 40617691)
35. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D., A β vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005 64 1 129 131 2-s2.0-19944429065 (Pubitemid 40082949)
36. Guénette S., Mechanisms of A β clearance and catabolism. NeuroMolecular Medicine 2003 4 3 147 160 10.1385/NMM:4:3:147 (Pubitemid 38049970)
37. Andreasen N., Sjögren M., Blennow K., CSF markers for Alzheimer's disease: total tau, phospho-tau and A β 42. World Journal of Biological Psychiatry 2003 4 4 147 155 2-s2.0-14644398469 10.1080/15622970310029912
38. Suo Z., Cox A. A., Bartelli N., Rasul I., Festoff B. W., Premont R. T., Arendash G. W., GRK5 deficiency leads to early Alzheimer-like pathology and working memory impairment. Neurobiology of Aging 2007 28 12 1873 1888 2-s2.0-35148836216 10.1016/j.neurobiolaging.2006.08.013 (Pubitemid 47539698)
39. Sun A., Nguyen X. V., Bing G., Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections. Journal of Histochemistry and Cytochemistry 2002 50 4 463 472 2-s2.0-0036193799 (Pubitemid 34250585)
40. Bussière T., Bard F., Barbour R., Grajeda H., Guido T., Khan K., Schenk D., Games D., Seubert P., Buttini M., Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive A β immunotherapy on their clearance. The American Journal of Pathology 2004 165 3 987 995 2-s2.0-4344565054 (Pubitemid 39129305)
41. Tomiyama T., Matsuyama S., Iso H., Umeda T., Takuma H., Ohnishi K., Ishibashi K., Teraoka R., Sakama N., Yamashita T., Nishitsuji K., Ito K., Shimada H., Lambert M. P., Klein W. L., Mori H., A mouse model of amyloid β oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. Journal of Neuroscience 2010 30 14 4845 4856 2-s2.0-77950617631 10.1523/JNEUROSCI.5825-09. 2010
42. Chen G., Chen K. S., Kobayashi D., Barbour R., Motter R., Games D., Martin S. J., Morris R. G. M., Active β -amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of β -amyloid. Journal of Neuroscience 2007 27 10 2654 2662 2-s2.0-33847776041 10.1523/JNEUROSCI.3710-06.2007 (Pubitemid 46393609)
43. Fu H. J., Liu B., Frost J. L., Lemere C. A., Amyloid- β immunotherapy for Alzheimer's disease. CNS and Neurological Disorders-Drug Targets 2010 9 2 197 206 2-s2.0-77949884626
44. Jones M., Cordell J. L., Beyers A. D., Tse A. G. D., Mason D. Y., Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. Journal of Immunology 1993 150 12 5429 5435 2-s2.0-0027300658 (Pubitemid 23180656)
45. Dudal S., Krzywkowski P., Paquette J., Morissette C., Lacombe D., Tremblay P., Gervais F., Inflammation occurs early during the A β deposition process in TgCRND8 mice. Neurobiology of Aging 2004 25 7 861 871 2-s2.0-3042567711 10.1016/j.neurobiolaging.2003.08.008 (Pubitemid 38813166)
46. Calhoun M. E., Burgermeister P., Phinney A. L., Stalder M., Tolnay M., Wiederhold K., Abramowski D., Sturchler-Pierrat C., Sommer B., Staufenbiel M., Jucker M., Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proceedings of the National Academy of Sciences of the United States of America 1999 96 24 14088 14093 2-s2.0-13044265226 10.1073/pnas.96.24.14088
47. Terai K., Iwai A., Kawabata S., Tasaki Y., Watanabe T., Miyata K., Yamaguchi T., β -amyloid deposits in transgenic mice expressing human β -amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 2001 104 2 299 310 2-s2.0-0035837274 10.1016/S0306-4522(01)00095-1 (Pubitemid 32493724)
48. Ruan L., Kang Z., Pei G., Le Y., Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Current Alzheimer Research 2009 6 6 531 540 2-s2.0-73949145739 10.2174/156720509790147070
49. Solomon B., Koppel R., Hanan E., Katzav T., Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide. Proceedings of the National Academy of Sciences of the United States of America 1996 93 1 452 455 2-s2.0-0030058382 10.1073/pnas.93.1.452 (Pubitemid 26038175)
50. Solomon B., Koppel R., Frankel D., Hanan-Aharon E., Disaggregation of Alzheimer β -amyloid by site-directed mAb. Proceedings of the National Academy of Sciences of the United States of America 1997 94 8 4109 4112 2-s2.0-0030971789 10.1073/pnas.94.8.4109 (Pubitemid 27180507)
51. Bard F., Cannon C., Barbour R., Burke R., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T., Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine 2000 6 8 916 919 2-s2.0-0033835996 10.1038/78682 (Pubitemid 30644751)
52. Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D., Hyman B. T., Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy. Journal of Neuroscience 2002 22 18 7873 7878 2-s2.0-0037107177 (Pubitemid 35379092)
53. Das P., Howard V., Loosbrock N., Dickson D., Murphy M. P., Golde T. E., Amyloid- β immunization effectively reduces amyloid deposition in FcR γ -/- knock-out mice. Journal of Neuroscience 2003 23 24 8532 8538 2-s2.0-0141457897 (Pubitemid 37158753)
54. Klyubin I., Walsh D. M., Lemere C. A., Cullen W. K., Shankar G. M., Betts V., Spooner E. T., Jiang L., Anwyl R., Selkoe D. J., Rowan M. J., Amyloid β protein immunotherapy neutralizes A β oligomers that disrupt synaptic plasticity in vivo. Nature Medicine 2005 11 5 556 561 2-s2.0-21044453723 10.1038/nm1234 (Pubitemid 40685979)
55. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G. M., Cooper N. R., Eikelenboom P., Emmerling M., Fiebich B. L., Finch C. E., Frautschy S., Griffin W. S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I. R., McGeer P. L., O'Banion M. K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., van Muiswinkel F. L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T., Inflammation and Alzheimer's disease. Neurobiology of Aging 2000 21 3 383 421 10.1016/S0197-4580(00)00124-X (Pubitemid 30349107)
56. Bornemann K. D., Staufenbiel M., Transgenic mouse models of Alzheimer's disease. Annals of the New York Academy of Sciences 2000 908 260 266 2-s2.0-0033943119 (Pubitemid 30462010)
57. Gordon M. N., Holcomb L. A., Jantzen P. T., DiCarlo G., Wilcock D., Boyett K. W., Connor K., Melachrino J., O'Callaghan J. P., Morgan D., Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Experimental Neurology 2002 173 2 183 195 2-s2.0-0036175608 10.1006/exnr.2001.7754 (Pubitemid 34151370)
58. Heneka M. T., Wiesinger H., Dumitrescu-Ozimek L., Riederer P., Feinstein D. L., Klockgether T., Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. Journal of Neuropathology and Experimental Neurology 2001 60 9 906 916 2-s2.0-0034836593 (Pubitemid 32880598)
59. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H., Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. Journal of Neurochemistry 2008 105 3 584 594 2-s2.0-42449107478 10.1111/j.1471-4159.2007.05147.x (Pubitemid 351562711)
60. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K. R., Paul S. M., Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid- β peptides. Nature Medicine 2004 10 7 719 726 2-s2.0-3142781310 10.1038/nm1058 (Pubitemid 38937637)
61. Duyckaerts C., Potier M., Delatour B., Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathologica 2008 115 1 5 38 2-s2.0-36949016215 10.1007/s00401-007-0312-8 (Pubitemid 50005258)
62. Matsuoka Y., Picciano M., Maleste B., LaFrancois J., Zehr C., Daeschner J. M., Olschowka J. A., Fonseca M. I., O'Banion M. K., Tenner A. J., Lemere C. A., Duff K., Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. The American Journal of Pathology 2001 158 4 1345 1354 2-s2.0-0035067311 (Pubitemid 32281298)
63. Itagaki S., McGeer P. L., Akiyama H., Zhu S., Selkoe D., Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of Neuroimmunology 1989 24 3 173 182 2-s2.0-0024436506 (Pubitemid 19271472)
64. Cotman C. W., Tenner A. J., Cummings B. J., β -amyloid converts an acute phase injury response to chronic injury responses. Neurobiology of Aging 1996 17 5 723 731 2-s2.0-0030250615 10.1016/0197-4580(96)00117-0 (Pubitemid 26348873)
65. Mrak R., Sheng J., Griffin W., Correlation of astrocytic S100b expression with dystrophic neurites in amyloid plaques of Alzheimer's disease. Journal of Neuropathology and Experimental Neurology 1996 55 4 273 279 10.1097/00005072- 199603000-00002
66. Town T., Vendrame M., Patel A., Poetter D., DelleDonne A., Mori T., Smeed R., Crawford F., Klein T., Tan J., Mullan M., Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's β -amyloid1-42. Journal of Neuroimmunology 2002 132 1-2 49 59 2-s2.0-0036850612 10.1016/S0165-5728(02) 00307-7 (Pubitemid 35333325)
67. Muhs A., Hickman D. T., Pihlgren M., Chuard N., Giriens V., Meerschman C., van der Auwera I., van Leuven F., Sugawara M., Weingertner M., Bechinger B., Greferath R., Kolonko N., Nagel-Steger L., Riesner D., Brady R. O., Pfeifer A., Nicolau C., Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2007 104 23 9810 9815 2-s2.0-34547473731 10.1073/pnas.0703137104 (Pubitemid 47175348)
68. Kitazawa M., Oddo S., Yamasaki T. R., Green K. N., LaFerla F. M., Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. Journal of Neuroscience 2005 25 39 8843 8853 2-s2.0-25644456097 10.1523/JNEUROSCI.2868-05.2005 (Pubitemid 41384452)
69. Panza F., Frisardi V., Solfrizzi V., Imbimbo B. P., Logroscino G., Santamato A., Greco A., Seripa D., Pilotto A., Immunotherapy for Alzheimer's disease: from anti- β -amyloid to tau-based immunization strategies. Immunotherapy 2012 4 2 213 238 2-s2.0-84857558439 10.2217/imt.11.170